Zhihao Lu
Peking University
9 Papers
87 Citations
Zhihao Lu is an academic researcher from Peking University. The author has contributed to research in topics: Capecitabine & Cancer. The author has an hindex of 7, co-authored 9 publications.
Chat about Author
Papers
The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
Zhi Peng,Siyuan Cheng,Yan Kou,Ziqi Wang,Rong Jin,Han Hu,Xiaotian Zhang,Jifang Gong,Jian Li,Ming Lu,Xicheng Wang,Jun Zhou,Zhihao Lu,Quan Zhang,David T.W. Tzeng,Dongtao Bi,Yan Tan,Lin Shen +17 more
TL;DR: The impact of gut microbiomes on anti–PD-1/PD-L1 outcomes is highlighted, at least in a subset of patients with GI cancer, and the potential of the microbiome as a marker for immune-checkpoint blockade responses is suggested.
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.
Ming Lu,Panpan Zhang,Yanqiao Zhang,Zhongwu Li,Jifang Gong,Jie Li,Jian Li,Yan Li,Xiaotian Zhang,Zhihao Lu,Xicheng Wang,Jun Zhou,Zhi Peng,Weifeng Wang,Hui Feng,Hai Wu,Sheng Yao,Lin Shen +17 more
TL;DR: Toripalimab had antitumor activity and safety in treating recurrent or metastatic NENs and patients with positive PD-L1 expression, TMB-H (top 10%), and/or microsatellite instable (MSI-H) might preferentially benefit from the treatment.
Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
Zhihao Lu,Jin Na Li,Ming Lu,Xiuru Zhang,Jun Zhou,Xing Wang,Jifang Gong,Jing Gao,Youbao Li,Li Shen +9 more
TL;DR: The irinotecan plus cisplatin chemotherapy is moderately effective and tolerable well tolerated in advanced or metastatic GEP-NEC patients; octreotide LAR may be a good maintenance treatment and should be considered as a treatment option for these patients in the future.
36
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first‐line chemotherapy
Furong Kou,Zhihao Lu,Jian Li,Xiaotian Zhang,Ming Lu,Jun Zhou,Xicheng Wang,Jifang Gong,Jing Gao,Jie Li,Yan Li,Lin Shen +11 more
TL;DR: It is shown that pretreatment lymphopenia is a good prognostic factor as well as a predictive factor for tumor response and chemotherapy‐related hematological toxicity in metastatic ESCC.
33
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
TL;DR: It is indicated that low levels of TUBB3 in serum could predict better response and survival for advanced gastric cancer patients receiving paclitaxel plus capecitabine, which could be used to select patients who would benefit from this regimen.
24